Back

Correlation of electrocardiographic reverse remodelling with treatment response to mavacamten in hypertrophic obstructive cardiomyopathy

31 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Cardiac myosin inhibitors: real-world data Hypertrophic Cardiomyopathy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Mustapha Menhem

University Hospital Erlangen, Erlangen (Germany)

5 More presentations in this session

Presentation thumbnail
Real-world data on the use of mavacamten in obstructive hypertrophic cardiomyopathy: one-year data from the multicentre MARVEL.HU study involving 133 patients
Doctor R. Sepp (Szeged, HU)
Abstract
Presentation thumbnail
Surgical myectomy after mavacamten discontinuation in obstructive hypertrophic cardiomyopathy: a real-world case series
Doctor C. Nie (Beijing, CN)
Abstract
Presentation thumbnail
Predictors of functional status and quality-of-life improvement with mavacamten in obstructive hypertrophic cardiomyopathy: one-year results from a real-world nationwide cohort
Doctor G. Bonacchi (Florence, IT)
Abstract
Presentation thumbnail
From evidence to practice: Mavacamten in obstructive Hypertrophic Cardiomyopathy - data from the multicenter TORCH-Plus-DZHK21 registry
Doctor J. Koelemen (Heidelberg, DE)
Abstract
Presentation thumbnail
Real-world experience and structural remodeling with cardiac myosin inhibitors in hypertrophic obstructive cardiomyopathy: Insights from a Heart Failure Network Registry
Doctor D. Jurczyk (Luebeck, DE)
Abstract

Access the full session

Session thumbnail
Cardiac myosin inhibitors: real-world data

The Event

Event poster

ESC Congress 2026

31 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
The effect of mavacamten on electrical parameters in cardiac implantable electronic devices
13 April 2026
thumbnail
Congress Presentation
High dosages of betablockers are related to left ventricular reverse remodelling in patients with recent-onset non-ischaemic dilated cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
Hypertrophic obstructive cardiomyopathy and magnetic resonance imaging: exploring the impact of mavacamten
9 May 2026
thumbnail
Congress Presentation
Mitral regurgitation in obstructive hypertrophic cardiomyopathy: assessing the impact of mavacamten
13 December 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources